In vitro models of lapatinib-acquired resistance HER2+ BC reveal that AXL effectively binds to the regulatory subunit p85 of PI3K, activating PI3K and circumventing the effects of lapatinib or trastuzumab. This evidence concerns the gene ERBB2 and breast cancer.